Previous close | 18.64 |
Open | 18.57 |
Bid | 18.60 x 100 |
Ask | 23.71 x 200 |
Day's range | 18.22 - 18.91 |
52-week range | 13.82 - 24.21 |
Volume | |
Avg. volume | 617,272 |
Market cap | 1.673B |
Beta (5Y monthly) | 1.98 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.18 |
Earnings date | 01 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 23.91 |
80% of people diagnosed with anxiety, depression report losing years or decades of timeSALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest GeneSight Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. Of those
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad’s prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. Prior studies from other commercial pcfDNA laboratories have reported a broad range of
Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.